Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Currently, no targeted therapies are available for metastatic triplenegative breast cancer (mTNBC). We evaluated the safety, efficacy, and biomarkers of response to cabozantinib, a multikinase inhibitor, in patients with mTNBC. We conducted a single arm phase II and biomarker study that enrolled pat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Tolaney, Sara M., Ziehr, David R., Guo, Hao, Ng, Mei R., Barry, William T., Higgins, Michaela J., Isakoff, Steven J., Brock, Jane E., Ivanova, Elena V., Paweletz, Cloud P., Demeo, Michelle K., Ramaiya, Nikhil H., Overmoyer, Beth A., Jain, Rakesh K., Winer, Eric P., Duda, Dan G.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2017
Предметы:
Breast Cancer
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5313267/
https://ncbi.nlm.nih.gov/pubmed/27789775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0229
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы